



Clinical trial results:

A randomised, open label study to evaluate the efficacy and safety of maraviroc(MVC) as a switch for N(t)RTI or PI/r in HIV1 infected individuals with stable, well controlled plasma HIV RNA while taking their first N(t)RTI + PI/r regimen of cART.

Summary

EudraCT number	2011-002107-15
Trial protocol	IE GB DE ES PL
Global end of trial date	19 December 2015

Results information

Result version number	v1 (current)
This version publication date	25 June 2022
First version publication date	25 June 2022
Summary attachment (see zip file)	MARCH week 48 results (MARCH week 48 results published in CID.full.pdf)

Trial information

Trial identification

Sponsor protocol code	HREC11342
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01384682
WHO universal trial number (UTN)	-
Other trial identifiers	Asutralian New Zealand Clinical Trials Registry: ACTRN12611000816954

Notes:

Sponsors

Sponsor organisation name	Kirby Institute, University of New South Wales
Sponsor organisation address	Wallace Wurth Building, Kensington, Australia, 2052
Public contact	Matthew Law, Kirby Institute, UNSW, 61 293850862, mlaw@kirby.unsw.edu.au
Scientific contact	Matthew Law, Kirby Institute, UNSW, 61 293850862, mlaw@kirby.unsw.edu.au

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 March 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	14 January 2015
Global end of trial reached?	Yes
Global end of trial date	19 December 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary research question is to determine whether a switch to maraviroc in HIV+ patients who are on a stable regimen of anti HIV drugs provides an optimal balance of safety, efficacy and tolerability across a range of populations. The primary endpoint of the study is the number of participants with HIV viral load (level of HIV in the blood) less than 200 copies at 48 weeks after randomisation.

Protection of trial subjects:

All subjects screened for CXCR4 virus as exclusion criteria.

Background therapy:

Not applicable.

Evidence for comparator:

Standard of care at the time was 2NRTI+PI combination antiretroviral therapy. There were concerns about long-term side effects of these drugs. This trial compared a strategy of switching subjects to maraviroc regimens, either NRTI or PI sparing.

Actual start date of recruitment	01 August 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 83
Country: Number of subjects enrolled	Australia: 19
Country: Number of subjects enrolled	Canada: 12
Country: Number of subjects enrolled	Chile: 10
Country: Number of subjects enrolled	Japan: 18
Country: Number of subjects enrolled	Mexico: 87
Country: Number of subjects enrolled	Thailand: 14
Country: Number of subjects enrolled	Poland: 68
Country: Number of subjects enrolled	Spain: 14
Country: Number of subjects enrolled	United Kingdom: 25
Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Germany: 37
Country: Number of subjects enrolled	Ireland: 2

Worldwide total number of subjects	395
EEA total number of subjects	127

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	382
From 65 to 84 years	13
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The first and last randomizations were 19 January 2012 and 12 February 2014, respectively. All participants completed 48 weeks of follow-up by 14 January 2015.

Pre-assignment

Screening details:

Participants were included if they were HIV-1-infected adults aged ≥ 18 years, with plasma HIV RNA (viral load [VL]) < 200 copies/mL on a stable (> 24 weeks) 2-N(t)RTI + PI/r regimen. Please attached week 48 final result for further details - not enough room here.

Period 1

Period 1 title	Treatment period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Control

Arm description:

Continue 2-N(t)RTI + PI/r regimen

Arm type	Active comparator
Investigational medicinal product name	2-N(t)RTI + PI/r
Investigational medicinal product code	NA
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oropharyngeal use

Dosage and administration details:

Subjects remained on their current antiretroviral regimen, keeping their current dosage schedule.

Arm title	Maraviroc + 2NRTI
------------------	-------------------

Arm description:

Switch from current regimen to Maraviroc+2NRTI

Arm type	Experimental
Investigational medicinal product name	Maraviroc + 2NRTI
Investigational medicinal product code	NA
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oropharyngeal use

Dosage and administration details:

Maraviroc 300 mg twice daily, 2NRTI backbone continued from original regimen according to that dosage schedule.

Arm title	Maraviroc + PIr
------------------	-----------------

Arm description:

Switch from current regimen to Maraviroc + ritonavir boosted PI

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Maraviroc + PIR
Investigational medicinal product code	NA
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oropharyngeal use

Dosage and administration details:

Maraviroc 150 mg twice daily, PIR continued from original regimen according to that dosage schedule

Number of subjects in period 1	Control	Maraviroc + 2NRTI	Maraviroc + PIR
Started	82	156	157
Completed	80	140	140
Not completed	2	16	17
Switched to other ARV regimen	-	-	13
Switched from randomised ART	1	-	-
Switched off randomised regimen	-	13	-
Lost to follow-up	1	1	1
Died	-	-	1
Withdrew	-	2	2

Baseline characteristics

Reporting groups

Reporting group title	Control
Reporting group description:	
Continue 2-N(t)RTI + PI/r regimen	
Reporting group title	Maraviroc + 2NRTI
Reporting group description:	
Switch from current regimen to Maraviroc+2NRTI	
Reporting group title	Maraviroc + PIR
Reporting group description:	
Switch from current regimen to Maraviroc + ritonavir boosted PI	

Reporting group values	Control	Maraviroc + 2NRTI	Maraviroc + PIR
Number of subjects	82	156	157
Age categorical			
Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			
Infants and toddlers (28 days-23 months)			
Children (2-11 years)			
Adolescents (12-17 years)			
Adults (18-64 years)			
From 65-84 years			
85 years and over			
Age continuous			
Mean age at randomisation			
Units: years			
arithmetic mean	43.6	43.7	42.7
standard deviation	± 10.5	± 10.5	± 9.6
Gender categorical			
Units: Subjects			
Female	20	35	35
Male	62	121	122
HIV RNA			
HIV RNA viral load			
Units: Subjects			
<50 copies/mL	79	151	150
>=50 copies/mL	3	5	7
CD4 count			
CD4 count			
Units: cells/microlitre			
arithmetic mean	634.8	596.3	637.6
standard deviation	± 244.5	± 253.3	± 252.7
Reporting group values	Total		

Number of subjects	395		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous			
Mean age at randomisation			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	90		
Male	305		
HIV RNA			
HIV RNA viral load			
Units: Subjects			
<50 copies/mL	380		
>=50 copies/mL	15		
CD4 count			
CD4 count			
Units: cells/microlitre			
arithmetic mean			
standard deviation	-		

End points

End points reporting groups

Reporting group title	Control
Reporting group description: Continue 2-N(t)RTI + PI/r regimen	
Reporting group title	Maraviroc + 2NRTI
Reporting group description: Switch from current regimen to Maraviroc+2NRTI	
Reporting group title	Maraviroc + PIr
Reporting group description: Switch from current regimen to Maraviroc + ritonavir boosted PI	
Subject analysis set title	Primary analysis
Subject analysis set type	Intention-to-treat
Subject analysis set description: All randomised subjects excluding those who withdrew consent (n=1) and those who did not attend baseline (n=1)	

Primary: HIV RNA <200 copies/mL 48 weeks

End point title	HIV RNA <200 copies/mL 48 weeks
End point description: Proportion of subjects in each randomised arm with HIV RNA <200 copies/mL at 48 weeks	
End point type	Primary
End point timeframe: At 48 weeks after randomisation	

End point values	Control	Maraviroc + 2NRTI	Maraviroc + PIr	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	82 ^[1]	156 ^[2]	157 ^[3]	
Units: Copies/mL				
<200 copies/mL	80	146	132	
≥200 copies/mL	2	9	25	

Notes:

[1] - ITT

[2] - ITT

[3] - ITT

Attachments (see zip file)	March virologic response/Time to loss of virologic response.
-----------------------------------	--

Statistical analyses

Statistical analysis title	Primary endpoint
Statistical analysis description: Comparison between randomised arms of proportion with undetectable viral load (<200 copies/mL) at week 48. Analysis was by intention to treat including all randomised participants excluding those who withdrew consent or did not attend baseline.	
Comparison groups	Maraviroc + 2NRTI v Control

Number of subjects included in analysis	238
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[4]
P-value	= 0.05 ^[5]
Method	Chi-squared
Parameter estimate	Difference in percentages
Point estimate	-4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-9.6
upper limit	2.2
Variability estimate	Standard deviation
Dispersion value	5.9

Notes:

[4] - Non-inferiority delta of 21%

[5] - 95% confidence intervals presented

Statistical analysis title	Copy of Primary endpoint
-----------------------------------	--------------------------

Statistical analysis description:

Comparison between randomised arms of proportion with undetectable viral load (<200 copies/mL) at week 48. Analysis was by intention to treat including all randomised participants excluding those who withdrew consent or did not attend baseline.

Comparison groups	Control v Maraviroc + PIR
Number of subjects included in analysis	239
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[6]
P-value	= 0.05 ^[7]
Method	Chi-squared
Parameter estimate	Difference in percentages
Point estimate	-13.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-19.8
upper limit	-5.8
Variability estimate	Standard deviation
Dispersion value	7

Notes:

[6] - Non-inferiority delta of 21%

[7] - 95% confidence intervals presented

Secondary: Change in CD4 count

End point title	Change in CD4 count
End point description:	
Change in CD4 count at week 48 from baseline	
End point type	Secondary
End point timeframe:	
Week 48	

End point values	Control	Maraviroc + 2NRTI	Maraviroc + PIs	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	82 ^[8]	156 ^[9]	157 ^[10]	
Units: cells/microlitre				
arithmetic mean (standard deviation)	40 (± 160)	39 (± 182)	29 (± 183)	

Notes:

[8] - ITT

[9] - ITT

[10] - ITT

Attachments (see zip file)	MARCH week 48 CD4/March change in CD4 count figure.docx
-----------------------------------	---

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

To week 48

Adverse event reporting additional description:

Adverse events assessed by clinical exam at weeks 4, 12, 24, 36 and 48 from randomisation.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.1
--------------------	------

Reporting groups

Reporting group title	Control
-----------------------	---------

Reporting group description:

Continue 2-N(t)RTI + PI/r regimen

Reporting group title	Maraviroc + 2NRTI
-----------------------	-------------------

Reporting group description:

Switch from current regimen to Maraviroc+2NRTI

Reporting group title	Maraviroc + PIr
-----------------------	-----------------

Reporting group description:

Switch from current regimen to Maraviroc + ritonavir boosted PI

Serious adverse events	Control	Maraviroc + 2NRTI	Maraviroc + PIr
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 82 (9.76%)	15 / 156 (9.62%)	14 / 157 (8.92%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Adenocarcinoma			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spine metastasis			

subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Acute myocardial infarction			
subjects affected / exposed	1 / 82 (1.22%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stroke			
subjects affected / exposed	1 / 82 (1.22%)	0 / 156 (0.00%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Surgical and medical procedures			
Anal fistula repair			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excision of right cervical lymphadenopathy			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion			

subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	2 / 157 (1.27%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Prolonged fever			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Metrorrhoea			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pneumonia with infiltrates			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			

subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COPD exacerbation			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenocarcinoma of lung			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 82 (0.00%)	4 / 156 (2.56%)	2 / 157 (1.27%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			
subjects affected / exposed	1 / 82 (1.22%)	0 / 156 (0.00%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Encephalopathy			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	2 / 157 (1.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphocytic meningitis			
subjects affected / exposed	1 / 82 (1.22%)	0 / 156 (0.00%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tremor			

subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervical lymphadenopathy			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 82 (1.22%)	1 / 156 (0.64%)	2 / 157 (1.27%)
occurrences causally related to treatment / all	0 / 1	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 82 (1.22%)	0 / 156 (0.00%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			

Acute hepatitis C			
subjects affected / exposed	0 / 82 (0.00%)	2 / 156 (1.28%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amebian liver abscess			
subjects affected / exposed	1 / 82 (1.22%)	0 / 156 (0.00%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Erysipelas			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head contusion			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Fractured malleolus			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			

subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Spinal disc herniation			
subjects affected / exposed	1 / 82 (1.22%)	0 / 156 (0.00%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	1 / 82 (1.22%)	0 / 156 (0.00%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 82 (0.00%)	1 / 156 (0.64%)	0 / 157 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
CMV colitis			
subjects affected / exposed	0 / 82 (0.00%)	0 / 156 (0.00%)	1 / 157 (0.64%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Control	Maraviroc + 2NRTI	Maraviroc + PIR
Total subjects affected by non-serious adverse events subjects affected / exposed	58 / 82 (70.73%)	120 / 156 (76.92%)	114 / 157 (72.61%)
Nervous system disorders Disturbances in initiating and maintaining sleep subjects affected / exposed occurrences (all)	6 / 82 (7.32%) 6	5 / 156 (3.21%) 5	4 / 157 (2.55%) 6
Headaches NEC subjects affected / exposed occurrences (all)	9 / 82 (10.98%) 14	12 / 156 (7.69%) 15	11 / 157 (7.01%) 13
General disorders and administration site conditions Asthenic conditions subjects affected / exposed occurrences (all)	4 / 82 (4.88%) 4	4 / 156 (2.56%) 4	13 / 157 (8.28%) 13
Blood and lymphatic system disorders Lymphatic system disorders NEC subjects affected / exposed occurrences (all)	5 / 82 (6.10%) 5	2 / 156 (1.28%) 3	7 / 157 (4.46%) 7
Gastrointestinal disorders Diarrhoea (excl infectious) subjects affected / exposed occurrences (all)	10 / 82 (12.20%) 13	9 / 156 (5.77%) 9	16 / 157 (10.19%) 22
Gastrointestinal atonic and hypomotility disorders NEC subjects affected / exposed occurrences (all)	3 / 82 (3.66%) 3	15 / 156 (9.62%) 16	4 / 157 (2.55%) 4
Oral soft tissue infections subjects affected / exposed occurrences (all)	2 / 82 (2.44%) 2	8 / 156 (5.13%) 10	3 / 157 (1.91%) 3
Respiratory, thoracic and mediastinal disorders Bronchospasm and obstruction subjects affected / exposed occurrences (all)	4 / 82 (4.88%) 4	3 / 156 (1.92%) 3	1 / 157 (0.64%) 1
Coughing and associated symptoms subjects affected / exposed occurrences (all)	5 / 82 (6.10%) 5	4 / 156 (2.56%) 4	4 / 157 (2.55%) 4
Lower respiratory tract infections			

NEC			
subjects affected / exposed	8 / 82 (9.76%)	19 / 156 (12.18%)	15 / 157 (9.55%)
occurrences (all)	8	23	17
Upper respiratory tract infection NEC			
subjects affected / exposed	24 / 82 (29.27%)	39 / 156 (25.00%)	37 / 157 (23.57%)
occurrences (all)	28	53	55
Viral upper respiratory tract infections			
subjects affected / exposed	3 / 82 (3.66%)	8 / 156 (5.13%)	13 / 157 (8.28%)
occurrences (all)	3	8	13
Skin and subcutaneous tissue disorders			
Dermatitis and eczema			
subjects affected / exposed	2 / 82 (2.44%)	9 / 156 (5.77%)	4 / 157 (2.55%)
occurrences (all)	2	11	4
Skin and subcutaneous tissue fungal infections			
subjects affected / exposed	2 / 82 (2.44%)	7 / 156 (4.49%)	11 / 157 (7.01%)
occurrences (all)	2	7	12
Rashes, eruptions and exanthems NEC			
subjects affected / exposed	0 / 82 (0.00%)	8 / 156 (5.13%)	7 / 157 (4.46%)
occurrences (all)	0	9	8
Renal and urinary disorders			
Genitourinary tract infections and inflammation NEC			
subjects affected / exposed	2 / 82 (2.44%)	9 / 156 (5.77%)	5 / 157 (3.18%)
occurrences (all)	2	9	5
Musculoskeletal and connective tissue disorders			
Joint related signs and symptoms			
subjects affected / exposed	5 / 82 (6.10%)	11 / 156 (7.05%)	9 / 157 (5.73%)
occurrences (all)	7	13	10
Musculoskeletal and connective tissue pain and discomfort			
subjects affected / exposed	8 / 82 (9.76%)	14 / 156 (8.97%)	9 / 157 (5.73%)
occurrences (all)	8	14	11
Metabolism and nutrition disorders			
Bone metabolism disorders			
subjects affected / exposed	9 / 82 (10.98%)	9 / 156 (5.77%)	11 / 157 (7.01%)
occurrences (all)	10	9	11

Metabolic disorders NEC subjects affected / exposed occurrences (all)	4 / 82 (4.88%) 5	0 / 156 (0.00%) 0	0 / 157 (0.00%) 0
---	---------------------	----------------------	----------------------

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported